Magnus Financial Group LLC Has $3.97 Million Stake in Johnson & Johnson $JNJ

Magnus Financial Group LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 41.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,402 shares of the company’s stock after selling 15,138 shares during the period. Magnus Financial Group LLC’s holdings in Johnson & Johnson were worth $3,968,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Norges Bank bought a new stake in Johnson & Johnson in the second quarter worth approximately $4,877,174,000. Laurel Wealth Advisors LLC grew its position in shares of Johnson & Johnson by 15,040.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after buying an additional 7,371,687 shares during the period. Vanguard Group Inc. increased its stake in shares of Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after acquiring an additional 2,557,388 shares during the period. Finally, Kingstone Capital Partners Texas LLC bought a new position in Johnson & Johnson during the second quarter worth $401,420,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

JNJ has been the topic of several research reports. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Wells Fargo & Company increased their price target on Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Argus set a $210.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. Finally, Royal Bank Of Canada set a $240.00 price target on shares of Johnson & Johnson in a research note on Wednesday, December 17th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $213.33.

Johnson & Johnson Stock Down 0.3%

Johnson & Johnson stock opened at $218.81 on Friday. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $220.11. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm’s 50-day simple moving average is $205.82 and its 200 day simple moving average is $186.95. The stock has a market cap of $527.18 billion, a PE ratio of 21.12, a price-to-earnings-growth ratio of 2.25 and a beta of 0.34.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.